Tokyo Tape
Sign in
← Chiome Bioscience

Quarterly report · Q1

4583.TEDINET S100QPID
Period2023-01-01 → 2023-03-31
Filed2023-05-11
StandardJapan GAAP
ConsolidatedNo
Data checks10 of 10 passed
Key figures · 32
MetricValuePeriodScopeSource row
Revenue¥169m2023-01-01 → 2023-03-31StandaloneNet sales
Revenue¥631m2022-01-01 → 2022-12-31StandaloneNet sales (5-year summary)
Revenue¥129m2022-01-01 → 2022-03-31StandaloneNet sales
Operating income−¥226m2023-01-01 → 2023-03-31StandaloneOperating income
Operating income−¥487m2022-01-01 → 2022-03-31StandaloneOperating income
Ordinary income−¥227m2023-01-01 → 2023-03-31StandaloneOrdinary income
Ordinary income−¥1.2bn2022-01-01 → 2022-12-31StandaloneOrdinary income loss (5-year summary)
Ordinary income−¥491m2022-01-01 → 2022-03-31StandaloneOrdinary income
Profit before tax−¥226m2023-01-01 → 2023-03-31StandaloneIncome before income taxes
Profit before tax−¥491m2022-01-01 → 2022-03-31StandaloneIncome before income taxes
Net income−¥228m2023-01-01 → 2023-03-31StandaloneProfit loss
Net income−¥1.2bn2022-01-01 → 2022-12-31StandaloneNet income loss (5-year summary)
Net income−¥492m2022-01-01 → 2022-03-31StandaloneProfit loss
Total assets¥2.1bnat 2023-03-31StandaloneAssets
Total assets¥2.2bnat 2022-12-31StandaloneAssets
Total assets¥2.1bnat 2022-03-31StandaloneTotal assets (5-year summary)
Total liabilities¥524mat 2023-03-31StandaloneLiabilities
Total liabilities¥425mat 2022-12-31StandaloneLiabilities
Net assets / equity¥1.6bnat 2023-03-31StandaloneNet assets
Net assets / equity¥1.8bnat 2022-12-31StandaloneNet assets
Net assets / equity¥1.7bnat 2022-03-31StandaloneNet assets (5-year summary)
Cash and deposits¥1.6bnat 2023-03-31StandaloneCash and deposits
Cash and deposits¥1.7bnat 2022-12-31StandaloneCash and deposits
EPS (basic)¥-4.72023-01-01 → 2023-03-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-28.262022-01-01 → 2022-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-11.662022-01-01 → 2022-03-31StandaloneBasic earnings loss per share (5-year summary)
Equity ratio74.3%at 2023-03-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio80.2%at 2022-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio76.3%at 2022-03-31StandaloneEquity to asset ratio (5-year summary)
Shares issued48,423,500at 2023-03-31StandaloneTotal number of issued shares (5-year summary)
Shares issued48,423,500at 2022-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued42,409,900at 2022-03-31StandaloneTotal number of issued shares (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 16
SegmentItemPeriodValue
Reconciling Itemsreconcilingsegment profit2023-01-01 → 2023-03-31−¥128m
jpcrp040300-q1r_E26096-000Drug Discovery And Developmentreportable segmentsegment profit2023-01-01 → 2023-03-31−¥194m
jpcrp040300-q1r_E26096-000Drug Discovery Supportreportable segmentrevenue2023-01-01 → 2023-03-31¥169m
jpcrp040300-q1r_E26096-000Drug Discovery Supportreportable segmentrevenue external2023-01-01 → 2023-03-31¥169m
jpcrp040300-q1r_E26096-000Drug Discovery Supportreportable segmentsegment profit2023-01-01 → 2023-03-31¥96m
Total Of Reportable Segments And Otherssegment totalrevenue2023-01-01 → 2023-03-31¥169m
Total Of Reportable Segments And Otherssegment totalrevenue external2023-01-01 → 2023-03-31¥169m
Total Of Reportable Segments And Otherssegment totalsegment profit2023-01-01 → 2023-03-31−¥98m
Reconciling Itemsreconcilingsegment profit2022-01-01 → 2022-03-31−¥111m
jpcrp040300-q1r_E26096-000Drug Discovery And Developmentreportable segmentsegment profit2022-01-01 → 2022-03-31−¥446m
jpcrp040300-q1r_E26096-000Drug Discovery Supportreportable segmentrevenue2022-01-01 → 2022-03-31¥129m
jpcrp040300-q1r_E26096-000Drug Discovery Supportreportable segmentrevenue external2022-01-01 → 2022-03-31¥129m
jpcrp040300-q1r_E26096-000Drug Discovery Supportreportable segmentsegment profit2022-01-01 → 2022-03-31¥71m
Total Of Reportable Segments And Otherssegment totalrevenue2022-01-01 → 2022-03-31¥129m
Total Of Reportable Segments And Otherssegment totalrevenue external2022-01-01 → 2022-03-31¥129m
Total Of Reportable Segments And Otherssegment totalsegment profit2022-01-01 → 2022-03-31−¥375m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 321
ItemContextValueUnit
Research and development expenses sgaCurrentYTDDuration_NonConsolidatedMember193637000JPY
Other sgaPrior1YTDDuration_NonConsolidatedMember111357000JPY
Other sgaCurrentYTDDuration_NonConsolidatedMember128297000JPY
Selling general and administrative expensesPrior1YTDDuration_NonConsolidatedMember557361000JPY
Selling general and administrative expensesCurrentYTDDuration_NonConsolidatedMember321934000JPY
Operating incomePrior1YTDDuration_NonConsolidatedMember-486520000JPY
Operating incomeCurrentYTDDuration_NonConsolidatedMember-225994000JPY
Interest income noiPrior1YTDDuration_NonConsolidatedMember10000JPY
Interest income noiCurrentYTDDuration_NonConsolidatedMember8000JPY
Foreign exchange gains noiPrior1YTDDuration_NonConsolidatedMember－JPY
Foreign exchange gains noiCurrentYTDDuration_NonConsolidatedMember55000JPY
Other noiPrior1YTDDuration_NonConsolidatedMember5000JPY
Other noiCurrentYTDDuration_NonConsolidatedMember364000JPY
Non operating incomePrior1YTDDuration_NonConsolidatedMember15000JPY
Non operating incomeCurrentYTDDuration_NonConsolidatedMember428000JPY
Interest expenses noePrior1YTDDuration_NonConsolidatedMember321000JPY
Interest expenses noeCurrentYTDDuration_NonConsolidatedMember337000JPY
Stock issuance cost noePrior1YTDDuration_NonConsolidatedMember1185000JPY
Stock issuance cost noeCurrentYTDDuration_NonConsolidatedMember875000JPY
Foreign exchange losses noePrior1YTDDuration_NonConsolidatedMember3176000JPY
Foreign exchange losses noeCurrentYTDDuration_NonConsolidatedMember－JPY
Share based payment expenses noePrior1YTDDuration_NonConsolidatedMember－JPY
Share based payment expenses noeCurrentYTDDuration_NonConsolidatedMember654000JPY
Other noePrior1YTDDuration_NonConsolidatedMember－JPY
Other noeCurrentYTDDuration_NonConsolidatedMember0JPY
Non operating expensesPrior1YTDDuration_NonConsolidatedMember4683000JPY
Non operating expensesCurrentYTDDuration_NonConsolidatedMember1867000JPY
Ordinary incomePrior1YTDDuration_NonConsolidatedMember-491189000JPY
Ordinary incomeCurrentYTDDuration_NonConsolidatedMember-227433000JPY
Gain on sales of noncurrent assets eiPrior1YTDDuration_NonConsolidatedMember－JPY
Gain on sales of noncurrent assets eiCurrentYTDDuration_NonConsolidatedMember73000JPY
Gain on reversal of subscription rights to shares eiPrior1YTDDuration_NonConsolidatedMember－JPY
Gain on reversal of subscription rights to shares eiCurrentYTDDuration_NonConsolidatedMember930000JPY
Extraordinary incomePrior1YTDDuration_NonConsolidatedMember－JPY
Extraordinary incomeCurrentYTDDuration_NonConsolidatedMember1003000JPY
Income before income taxesPrior1YTDDuration_NonConsolidatedMember-491189000JPY
Income before income taxesCurrentYTDDuration_NonConsolidatedMember-226430000JPY
Income taxes currentPrior1YTDDuration_NonConsolidatedMember1252000JPY
Income taxes currentCurrentYTDDuration_NonConsolidatedMember1252000JPY
Income taxesPrior1YTDDuration_NonConsolidatedMember1252000JPY
Income taxesCurrentYTDDuration_NonConsolidatedMember1252000JPY
Profit lossPrior1YTDDuration_NonConsolidatedMember-492441000JPY
Profit lossCurrentYTDDuration_NonConsolidatedMember-227683000JPY
Revenues from external customersPrior1YTDDuration_NonConsolidatedMember_jpcrp040300-q1r_E26096-000DrugDiscoveryAndDevelopmentReportableSegmentsMember－JPY
Revenues from external customersPrior1YTDDuration_NonConsolidatedMember_jpcrp040300-q1r_E26096-000DrugDiscoverySupportReportableSegmentsMember128571000JPY
Revenues from external customersPrior1YTDDuration_NonConsolidatedMember_TotalOfReportableSegmentsAndOthersMember128571000JPY
Revenues from external customersPrior1YTDDuration_NonConsolidatedMember_ReconcilingItemsMember－JPY
Revenues from external customersPrior1YTDDuration_NonConsolidatedMember128571000JPY
Transactions with other segmentsPrior1YTDDuration_NonConsolidatedMember_jpcrp040300-q1r_E26096-000DrugDiscoveryAndDevelopmentReportableSegmentsMember－JPY
Transactions with other segmentsPrior1YTDDuration_NonConsolidatedMember_jpcrp040300-q1r_E26096-000DrugDiscoverySupportReportableSegmentsMember－JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 10 of 10 passed
balance sheet identitynon_consolidated 2022-12-31pass
balance sheet identitynon_consolidated 2023-03-31pass
dei present pass
period resolution pass
statement vs summary · net assetsnon_consolidated 2022-12-31pass
statement vs summary · net assetsnon_consolidated 2023-03-31pass
statement vs summary · revenuenon_consolidated 2022-01-01/2022-03-31pass
statement vs summary · revenuenon_consolidated 2023-01-01/2023-03-31pass
statement vs summary · total assetsnon_consolidated 2022-12-31pass
statement vs summary · total assetsnon_consolidated 2023-03-31pass